Amalgamated Bank Has $673,000 Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Amalgamated Bank lowered its position in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 2.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 19,949 shares of the company’s stock after selling 458 shares during the period. Amalgamated Bank’s holdings in Pacira BioSciences were worth $673,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in PCRX. Pacer Advisors Inc. boosted its position in Pacira BioSciences by 397,487.4% during the fourth quarter. Pacer Advisors Inc. now owns 1,041,679 shares of the company’s stock worth $35,146,000 after purchasing an additional 1,041,417 shares during the period. Rubric Capital Management LP bought a new stake in Pacira BioSciences during the third quarter worth approximately $14,102,000. Assenagon Asset Management S.A. boosted its position in Pacira BioSciences by 185.2% during the fourth quarter. Assenagon Asset Management S.A. now owns 246,621 shares of the company’s stock worth $8,321,000 after purchasing an additional 160,149 shares during the period. Eagle Asset Management Inc. boosted its position in Pacira BioSciences by 84.8% during the third quarter. Eagle Asset Management Inc. now owns 136,393 shares of the company’s stock worth $4,185,000 after purchasing an additional 62,597 shares during the period. Finally, Rice Hall James & Associates LLC boosted its position in Pacira BioSciences by 6.8% during the third quarter. Rice Hall James & Associates LLC now owns 968,485 shares of the company’s stock worth $29,713,000 after purchasing an additional 61,680 shares during the period. Institutional investors and hedge funds own 99.73% of the company’s stock.

Insiders Place Their Bets

In other Pacira BioSciences news, Director Gary W. Pace sold 90,000 shares of the stock in a transaction on Friday, March 8th. The stock was sold at an average price of $30.60, for a total transaction of $2,754,000.00. Following the completion of the transaction, the director now directly owns 22,127 shares in the company, valued at $677,086.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Pacira BioSciences news, Director Gary W. Pace sold 90,000 shares of the stock in a transaction on Friday, March 8th. The stock was sold at an average price of $30.60, for a total transaction of $2,754,000.00. Following the completion of the transaction, the director now directly owns 22,127 shares in the company, valued at $677,086.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Gary W. Pace sold 1,066 shares of the stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $29.67, for a total value of $31,628.22. Following the transaction, the director now owns 140,384 shares of the company’s stock, valued at $4,165,193.28. The disclosure for this sale can be found here. Corporate insiders own 6.40% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on PCRX shares. TheStreet raised Pacira BioSciences from a “d+” rating to a “c” rating in a research report on Thursday, February 29th. Royal Bank of Canada reduced their price objective on Pacira BioSciences from $53.00 to $45.00 and set an “outperform” rating for the company in a research report on Friday, March 1st. JPMorgan Chase & Co. initiated coverage on Pacira BioSciences in a research report on Thursday, March 7th. They issued an “overweight” rating and a $45.00 price objective for the company. Barclays reduced their price objective on Pacira BioSciences from $40.00 to $38.00 and set an “overweight” rating for the company in a research report on Wednesday, May 8th. Finally, HC Wainwright reissued a “buy” rating and issued a $57.00 price objective on shares of Pacira BioSciences in a research report on Wednesday, May 8th. Eleven analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $47.40.

Pacira BioSciences Stock Down 2.2 %

Shares of PCRX stock opened at $30.82 on Friday. The stock has a market cap of $1.43 billion, a P/E ratio of 21.55 and a beta of 0.77. Pacira BioSciences, Inc. has a one year low of $25.33 and a one year high of $42.63. The stock has a fifty day moving average price of $28.36 and a 200 day moving average price of $29.61. The company has a debt-to-equity ratio of 0.57, a current ratio of 5.81 and a quick ratio of 4.78.

Pacira BioSciences (NASDAQ:PCRX) last released its quarterly earnings data on Thursday, February 29th. The company reported $0.71 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.71. Pacira BioSciences had a return on equity of 12.98% and a net margin of 10.34%. The firm had revenue of $181.24 million during the quarter, compared to analyst estimates of $180.60 million. Analysts predict that Pacira BioSciences, Inc. will post 2.12 earnings per share for the current year.

Pacira BioSciences Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.